Sinopharm’s latest Sustainability Report details a year-long push to embed environmental, social and governance (ESG) principles throughout its pharmaceutical distribution, medical-device and retail operations.
Key operational achievements • Quality management: All 75 core subsidiaries hold ISO 9001 certificates; product self-inspection and external sampling pass rates both hit 100%, and no company-related product recalls were recorded. Client satisfaction reached 99.47%. • Network expansion: SPS+ professional pharmacies rose to 1,461 outlets across China’s 31 provincial-level regions, supported by more than 1,100 dual-channel medical-insurance drugstores and around 900 medical-insurance service centres. • Supply-chain reach: Sinopharm serves 46,788 suppliers worldwide and maintained a 100% supervision and audit coverage rate.
Environmental performance • Scope 1 greenhouse gas (GHG) emissions fell 1.11% year on year to 43,867.42 tCO₂e; Scope 2 emissions declined 5.77% to 167,039.94 tCO₂e, bringing total GHG emissions to 211,806.93 tCO₂e. • Total energy use decreased 6.81% to 491,105.91 MWh. • Industrial subsidiaries achieved 100% ISO 14001 environmental-management certification; 83 units now hold ISO 45001 occupational-health & safety certification. • The company’s Shanghai Kangning Road logistics park is fully carbon-neutral; similar certifications are under way in Shenyang, Guangzhou and Nanchang.
Workforce and governance • Staff training covered 100% of employees, averaging 65.10 hours per capita; anti-corruption training reached all 94,910 employees and all directors. • Employment-agreement signing rate stands at 100%; no incidents of child or forced labour were reported. • Pre-job safety-training coverage and pass rate for new hires achieved 100%; no work-related fatalities were recorded.
Social contribution • Employee volunteer service reached 50,244 hours across 5,821 attendances. • Charitable donations totalled RMB 7.54 million, including rapid medical-supply support during extreme weather events in Guizhou, Beijing and Gansu. • Rural-revitalisation initiatives added RMB 1.10 million in industrial sales and more than RMB 7.00 million through consumption-based assistance.
Looking ahead The Board reaffirmed Sinopharm’s 15th Five-Year Plan priorities: strengthen core competitiveness, accelerate digital and green transformation, maintain zero major quality incidents and deepen nationwide access to innovative medicines via its expanding SPS+ network.